MECHELEN, BELGIUM--(Marketwired - May 17, 2013) - Galapagos NV (Euronext: GLPG) announced
that the operational and financial results achieved thus far in 2013
the Company to retain full year 2013 Group revenues guidance of EUR160
"Galapagos has a maturing and broad pipeline of novel mode of action
Our flagship program, GLPG0634, will start a large Phase 2b study next
and both we and our partner AbbVie are excited about the opportunities of
molecule for the safe treatment of rheumatoid arthritis and other
diseases," said Onno van de Stolpe, CEO of Galapagos. "In our
portfolio, we now have three programs in Phase 2 studies in four
disease areas, and we are well on track to having multiple Phase 1 programs
novel, proprietary modes of action by end 2013."
In the first quarter of 2013, Galapagos reported substantial progress in
On the clinical development side, GlaxoSmithKline (GSK) initiated a
study with GSK2586184 (formerly GLPG0778) in chronic plaque psoriasis
Phase 2 study in systemic lupus erythematosus. This compound was
in-licensed by GSK in February 2012. In our proprietary program GLPG0974,
an inhibitor of FFA2
(free fatty acid receptor 2, formerly known as GPR43), a second Phase 1
confirmed that GLPG0974 was safe and well tolerated at all dose levels.
positive outcome of this study supported progression to a Phase 2
Concept study in ulcerative colitis patients, which started in April
GLPG0974 is the third compound from Galapagos' pipeline to enter
studies, and its first drug for patients with gastro-intestinal
On selective JAK1 inhibitor GLPG0634, Galapagos presented the
expanded scope of the Phase 2b program, which will start in Q2 2013.
paid Galapagos an additional $20 million to support the expanded scope of
program. Galapagos also announced that it plans to initiate clinical
with GLPG1790, a novel candidate drug with high efficacy against
triple-negative breast cancer.
In its alliances, Galapagos announced the successful delivery of a fifth
pre-clinical candidate drug in its alliance with GSK, triggering a
payment. A second pre-clinical compound was identified in its alliance
Janssen Pharmaceutica NV, triggering a milestone payment of EUR4
Galapagos. Galapagos received payments totalling EUR7.5 million
achievement of milestones in the osteoarthritis and oncology alliances
Servier. Roche and Galapagos agreed to end their alliance in
Galapagos received EUR5.75 million for work performed in 2012 and
worldwide rights to all fibrosis assays and the targets discovered
alliance. All of these alliance payments contributed to 2012 Group
The Flemish agency for Innovation by Science and Technology (IWT)
Galapagos two grants: EUR2.7 million to discover new antibiotic
EUR2.5 million for inflammatory bowel disease research and development.
Galapagos hosted its R&D Update in New York on March 27th. Galapagos
the progress and plans for its portfolio of more than 40 research
development programs. In addition to advances already described
Galapagos presented three Cystic fibrosis corrector programs in early
discovery and a potentiator program which is expected to deliver a
pre-clinical candidate by the end of 2013. The Company also announced the
termination of the
osteoporosis alliance with Lilly.
In other areas, Argenta announced a drug discovery collaboration with
Galapagos acquired Cangenix to add structure-based drug discovery
Argenta service offering. Galapagos also created Fidelta, a third
division for the Group. Katrine Bosley was appointed to Galapagos'
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline of four clinical, seven
pre-clinical, and 30 discovery small-molecule and antibody programs
in cystic fibrosis, inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
of rheumatoid arthritis and potentially other inflammatory diseases,
enter Phase 2b studies in RA and Phase 2 studies in Crohn's disease.
Galapagos signed a worldwide license agreement whereby AbbVie
responsible for further development and commercialization after Phase
Galapagos has another selective JAK1 inhibitor in Phase 2 in lupus
psoriasis, GSK2586184 (formerly GLPG0778, in-licensed by
2012). GLPG0187 is a novel integrin receptor antagonist currently in a
1b patient study in metastasis. GLPG0974 is the first inhibitor of GPR43
evaluated clinically for the treatment of IBD; this program is currently
Proof of Concept Phase 2 study.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information at:
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
Galapagos business update:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE